A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients

G Absenger\textsuperscript{1,2}, J Szkandera\textsuperscript{1,2}, M Pichler\textsuperscript{1}, M Stotz\textsuperscript{1}, F Arminger\textsuperscript{1}, M Weissmueller\textsuperscript{1}, R Schaberl-Moser\textsuperscript{1}, H Samonigg\textsuperscript{1}, T Stojakovic\textsuperscript{3} and A Gerger \textsuperscript{*1,2}

\textsuperscript{1}Division of Clinical Oncology, Department of Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria; \textsuperscript{2}Research Unit Genetic Epidemiology and Pharmacogenetics, Division of Clinical Oncology, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria and \textsuperscript{3}Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria

Background: Inflammation has a critical role in the pathogenesis and progression of cancer. Recently, the derived neutrophil to lymphocyte ratio (absolute count of neutrophils divided by the absolute white cell count minus the absolute count of neutrophils; dNLR) has been shown to influence clinical outcome in various cancer entities. In this study, we analysed the dNLR with clinical outcome in stage II and III colon cancer patients.

Methods: Three-hundred and seventy-two patients with stage II and III colon cancer were included in this retrospective study. Kaplan–Meier curves and multivariate Cox proportion analyses were calculated for time to recurrence (TTR) and overall survival (OS).

Results: In univariate analysis, the elevated preoperative dNLR was significantly associated with decreased TTR (hazard ratio (HR) 2.38, 95% confidence interval (CI) 1.57–3.6, \(P < 0.001\)) and remained significant in multivariate analysis. Patients with dNLR \(>3\) had a median TTR of 83 months, and patients with dNLR \(\leq 3\) showed a median TTR of 132 months. In OS analysis, a dNLR \(>2.2\) was significantly associated with decreased OS in univariate (HR 1.85, 95% CI 1.11–3.08, \(P = 0.018\)) and multivariate analysis. Patients with dNLR \(>2.2\) showed a median OS of 121 months, and patients with dNLR \(\leq 2.2\) had a median OS of 147 months.

Conclusion: The dNLR may be an independent prognostic marker for TTR and OS in patients with stage II and III colon cancer. Independent validation of our findings is warranted.
O’Connell et al., 2004; Morris et al., 2006; Quah et al., 2008). In addition, a large number of translational research studies evaluated the association of various molecular biomarkers with clinical outcome in colon cancer, but high costs, lack of standardisation and regional availability limit the application in routine clinical practice (Roth et al., 2010; Salazar et al., 2011).

It is widely accepted that inflammation has a critical role in the pathogenesis and progression of cancer. Genetic alterations, which activate oncogenes or result in the inactivation of tumour-suppressor genes, induce the transcription of inflammatory mediators. This generates a tumour-related inflammatory micro-environment and could explain the presence of inflammatory cells in tumours without epidemiological evidence for inflammation (Mantovani et al., 2008). On the other hand, systemic inflammatory response to tumours causes changes in the haematological components like white blood cells, specifically the neutrophils, lymphocytes and monocytes. The relative value of a combined index of neutrophil and lymphocyte counts (neutrophil to lymphocyte ratio, NLR) has been shown to influence the clinical outcome in various cancer entities, including cervical carcinoma (Lee et al., 2012), kidney cancer (Pichler et al., 2013), gastrointestinal cancers (Walsh et al., 2005; Kishi et al., 2009; Ding et al., 2010) and lung cancer (Sarraf et al., 2009). Recently, a derived score composed of white cell and neutrophil counts (absolute count of neutrophils divided by the absolute white cell count minus the absolute count of neutrophils; dNLR) has been evaluated in a large number of cancer patients, showing similar prognostic value to the NLR (Proctor et al., 2012). Because there is a wealth of clinical trial data, where only white cell and neutrophil counts have been recorded in computer databases, which could be used to examine, in detail, the clinical value of the haematopoietic tissue-derived systemic inflammatory response, the present study specifically evaluated the effect of the preoperative dNLR on time to recurrence (TTR) and overall survival (OS) in patients with stage II and III colon cancer (Proctor et al., 2012).

**MATERIALS AND METHODS**

**Subjects.** A total of 372 patients with histologically confirmed stage II and III colon cancer were included in this retrospective study. All patients were treated and/or included in the colon cancer surveillance program between 1996 and 2011 at the Division of Clinical Oncology, Department of Medicine, Medical University of Graz, Austria. Follow-up care was performed in regular intervals (3-month interval in years 1–3, 6-month interval in years 4–5 and 12-month interval in years 6–10 after diagnosis). Follow-up investigations included clinical examination, laboratory including CEA and carbohydrate antigen 19-9, radiological assessment (liver scan or ultrasound and chest X-ray every 6 months within the first 3 years) and colonoscopy every 2 years. Clinical and histopathological features were retrospectively obtained from the patient’s history. Follow-up data of all patients were available. The preoperative white blood cell count was obtained within 3 days before surgery. The dNLR was calculated as the absolute count of neutrophils divided by the absolute white cell count of leucocytes minus the absolute count of neutrophils. This study was approved by the Institutional Review Board of the Medical University of Graz. All participants were Caucasians. **Statistical analyses.** The primary endpoint of the study was TTR; the secondary endpoint was OS. Time to recurrence was calculated from the date of diagnosis of colon cancer to the date of tumour recurrence and was censored at the time of death or at the last follow-up if the patients remained tumour-free at that time. Overall survival was calculated from the time of diagnoses to the date of death of any cause. The optimal cut-off levels for the dNLR were determined by applying receiver operating curve (ROC) analysis. The dNLR was correlated with the clinicopathological features by χ²-test. The association between the clinicopathological features and the dNLR with TTR and OS was analysed using Kaplan–Meier curves and compared by the log-rank test. In the multivariate Cox-regression analysis, the model was adjusted for prognostic clinicopathological factors significantly associated with TTR and OS in univariate analysis. Hazard ratios (HRs) estimated from the Cox analysis were reported as relative risks with corresponding 95% confidence intervals (CIs). All statistical analyses were performed using the Statistical Package for Social Sciences version 20.0 (SPSS Inc., Chicago, IL, USA). A two-sided P<0.05 was considered statistically significant.

**RESULTS**

Baseline patient characteristics and tumour biological factors are shown in Table 1. The median age at time of diagnosis was 64 years (range 27–95 years). The median follow-up time was 68 months (range 1–190 months). Applying ROC analysis, the optimal cut-off levels for the dNLR was 3 for TTR and 2.2 for OS, respectively. For the NLR, ROC analysis provided an optimal cut-off level of 3.7 for TTR and 4 for OS. The ROC curves are shown in Supplementary Figures 1 and 2. The ROC curves for dNLR and NLR were 0.619 (P=0.0005) and 0.639 (P<0.0001) for TTR, respectively. The ROC curves for dNLR and NLR were 0.599 (P=0.008) and 0.625 (P=0.0004) for OS, respectively. The Spearman’s rank correlation between the dNLR and NLR was 0.938 (P<0.001). The dNLR and NLR were available in 354 (95.2%) out of 372 patients.

In our study cohort, we found a significant association between tumour-invasion depth, lymph node involvement and clinical stage with TTR and OS (Table 1). Because clinical stage derives from tumour-invasion depth and lymph node involvements, only clinical stage was included in further multivariate models.

None of the clinicopathological features were associated with the dNLR (Supplementary Table 1).

Of the 372 colon cancer patients, 94 (25.3%) developed tumour recurrence and 72 (19.4%) died within the follow-up period. The tumour recurred in 50 (20.1%) out of 249 patients with a dNLR ≤3 and in 41 (39%) out of 105 patients with a dNLR >3 (P<0.001). Death occurred in 23 (14.1%) out of 140 patients with a dNLR ≤2.2 and in 46 (31.7%) out of 145 patients with a dNLR >2.2 (P=0.018), respectively.

Three-year, 5-year and 10-year recurrence-free survival was 83.9%, 80.7% and 79.9% in patients with dNLR ≤3 and 61.9%, 61% and 61% in patients with dNLR >3 (P<0.001). Survival rates were 92.6%, 89.6% and 86.5% in patients with dNLR ≤2.2 and 81.7% (P=0.002), 77% (P=0.002) and 75.9% (P=0.012) in patients with dNLR >2.2, respectively.

In univariate analysis, the elevated preoperative dNLR was significantly associated with decreased TTR (HR 2.38, 95% CI 1.57–3.6, P<0.001; Figure 1) and remained significant in the multivariate analysis including clinical stage (HR 2.25, 95% CI 1.48–3.4, P<0.001; clinical stage: HR 2.27, 95% CI 1.4–3.67, P<0.001). Patients with a dNLR >3 had a median TTR of 83 months, whereas patients with a dNLR ≤3 showed a median TTR of 132 months. In OS analysis, the elevated preoperative dNLR was significantly associated with decreased OS in univariate analysis (HR 1.85, 95% CI 1.11–3.08, P=0.018; Figure 2) and multivariate analysis including clinical stage (HR 1.78, 95% CI 1.07–2.97, P=0.026; clinical stage: HR 1.95, 95% CI 1.14–3.35, P=0.016). Patients with a dNLR >2.2 showed a median OS of 121 months, whereas patients with a dNLR ≤2.2 had a median OS of 147 months.
In interaction analysis for TTR, there was a significant association between dNLR and adjuvant chemotherapy \((P = 0.015)\). Including only patients who underwent curative surgery alone, we found a significant association between dNLR and TTR in uni- and multivariate analysis (HR 3.44, 95% CI 1.70–6.99, \(P = 0.001\) and HR 3.03, 95% CI 1.47–6.14, \(P = 0.03\), respectively; Figure 3; clinical stage in multivariate analysis: HR 3.17, 95% CI 1.53–6.59, \(P = 0.002\)). In patients who underwent adjuvant chemotherapy, the association was also significant, however, with a lower HR (univariate: HR 1.91, 95% CI 1.14–3.21, \(P = 0.014\); multivariate: HR 1.84, 95% CI 1.1–3.1, \(P = 0.021\); Figure 4; clinical stage in multivariate analysis: HR 2.47, 95% CI 1.12–65.43, \(P = 0.025\)).

To analyse how our ROC analysis-based threshold level compares with the dNLR threshold level for OS in the subgroup of colorectal cancer patients provided by Proctor et al (2012), we validated the cut-off level of 2 in our study cohort (Guthrie et al, 2013). In univariate analysis, the dNLR \(\geq 2\) was significantly associated with decreased OS (HR 1.72, 95% CI 1.01–2.92, \(P < 0.046\)) but lost its significance in the multivariate analysis including clinical stage (HR 1.65, 95% CI 0.97–2.8, \(P < 0.066\); clinical stage: HR 1.96, 95% CI 1.14–3.37, \(P = 0.015\)). Patients with a dNLR \(\geq 2\) had a median OS of 123 months, whereas patients with a dNLR < 2 showed a median OS of 147 months.

In a second step, we analysed the association between NLR based on ROC analysis-derived cut-off levels and TTR and OS. In univariate analysis, the elevated preoperative NLR was significantly associated with decreased TTR (HR 2.46, 95% CI 1.6–3.78, \(P < 0.001\)) and remained significant in the multivariate analysis including clinical stage (HR 2.36, 95% CI 1.48–3.75, \(P < 0.001\); clinical stage: HR 1.86, 95% CI 1.12–3.11, \(P = 0.017\)). Patients with a NLR \(\geq 3.7\) had a median TTR of 104 months whereas patients with a NLR < 3.7 showed a median TTR of 138 months. In OS analysis, the elevated preoperative NLR was significantly associated with decreased OS in univariate analysis (HR 2.34, 95% CI 1.43–3.81, \(P = 0.001\)) and multivariate analysis (HR 2.22, 95% CI 1.36–3.62, \(P = 0.002\); clinical stage: HR 1.85, 95% CI 1.01–3.19, \(P = 0.026\)). Patients with a NLR > 4 showed a median OS of 113 months, whereas patients with a NLR \(\leq 4\) had a median OS of 150 months.

| Parameter | n   | %    | HR (95% CI) | \(P\)-value | HR (95% CI) | \(P\)-value |
|-----------|-----|------|-------------|-------------|-------------|-------------|
| **Gender** |     |      |             |             |             |             |
| Male      | 217 | 58.3 | 1 (reference) | 0.417       | 1 (reference) | 0.801       |
| Female    | 155 | 41.7 | 1.19 (0.80–1.79) | 0.015       | 1.06 (0.66–1.70) | 0.681       |
| **Tumour location** |     |      |             |             |             |             |
| Left      | 130 | 34.9 | 1 (reference) | 0.781       | 1 (reference) | 0.273       |
| Right     | 242 | 65.1 | 1.06 (0.69–1.63) | 0.77 (0.48–1.23) | 0.77 (0.48–1.23) | 0.273       |
| **Tumour-invasion depth** |     |      |             |             |             |             |
| T1        | 7   | 1.9  | 1 (reference) | 0.010       | <0.001      | <0.001      |
| T2        | 18  | 4.8  | 0.65 (0.06–7.17) | 0.77 (0.48–1.23) | 0.77 (0.48–1.23) | 0.273       |
| T3        | 260 | 69.9 | 1.43 (0.20–10.34) | 0.77 (0.48–1.23) | 0.77 (0.48–1.23) | 0.273       |
| T4        | 87  | 23.4 | 2.78 (0.38–20.36) | 0.77 (0.48–1.23) | 0.77 (0.48–1.23) | 0.273       |
| **Lymph node involvement** |     |      |             |             |             |             |
| N0        | 156 | 41.9 | 1 (reference) | <0.001      | 1 (reference) | <0.001      |
| N1        | 142 | 38.2 | 1.47 (0.87–2.48) | 1.25 (0.69–2.26) | 1.25 (0.69–2.26) | 0.273       |
| N2        | 73  | 19.6 | 4.02 (2.42–6.69) | 3.28 (1.85–5.83) | 3.28 (1.85–5.83) | 0.273       |
| Unknown   | 1   | 0.3  |             |             |             |             |
| **Tumour grade** |     |      |             |             |             |             |
| G1        | 23  | 6.2  | 1 (reference) | 0.776       | 1 (reference) | 0.273       |
| G2        | 240 | 64.5 | 1.39 (0.51–3.83) | 0.78 (0.28–2.20) | 0.78 (0.28–2.20) | 0.273       |
| G3        | 107 | 28.8 | 1.46 (0.51–4.16) | 1.34 (0.47–3.83) | 1.34 (0.47–3.83) | 0.273       |
| Unknown   | 2   | 0.5  |             |             |             |             |
| **Tumour stage** |     |      |             |             |             |             |
| II        | 154 | 41.4 | 1 (reference) | <0.001      | 1 (reference) | 0.273       |
| III       | 217 | 58.3 | 2.36 (1.48–3.75) | 1.86 (1.12–3.11) | 1.86 (1.12–3.11) | 0.273       |
| Unknown   | 1   | 0.3  |             |             |             |             |
| **Adjuvant chemotherapy** |     |      |             |             |             |             |
| No        | 141 | 37.9 | 1 (reference) | 0.605       | 1 (reference) | 0.181       |
| Yes       | 230 | 61.8 | 1.12 (0.73–1.72) | 0.73 (0.73–1.72) | 0.73 (0.73–1.72) | 0.273       |
| Unknown   | 1   | 0.3  |             |             |             |             |

Abbreviations: CI = confidence interval; HR = hazard ratio; na = not applicable; OS = overall survival; TTR = time to recurrence.
We then analysed the NLR with a predefined cut-off level of 5 based on previous studies evaluating early-stage colon cancer patients (Guthrie et al, 2013). In univariate analysis, the elevated preoperative NLR was significantly associated with decreased TTR (HR 1.91, 95% CI 1.26–2.9, P = 0.002) and remained significant in the multivariate analysis including clinical stage (HR 2.31, 95% CI 1.43–3.73, P = 0.001). Patients with a NLR ≥5 had a median TTR of 88 months, whereas patients with a NLR <5 showed a median TTR of 129 months. In OS analysis, the elevated preoperative NLR was significantly associated with decreased OS in univariate analysis (HR 1.82, 95% CI 1.12–2.94, P = 0.016) and multivariate analysis (HR 1.68, 95% CI 1.03–2.73, P = 0.037; clinical stage: HR 1.91, 95% CI 1.11–3.29, P = 0.019). Patients with a NLR ≥5 showed a median OS of 113 months, whereas patients with a NLR <5 had a median OS of 143 months.

**DISCUSSION**

The results of our study show that the dNLR is an independent prognostic marker in our study cohort including patients with stage II and III colon cancer. The derived ratio of neutrophils to leukocytes minus neutrophils may reflect the systemic response of the host to the tumour. Several translational research studies already demonstrated an effect of changes in white blood cells counts on clinical outcome in various cancer entities (Ege et al, 2008; Halazun et al, 2009; Kishi et al, 2009; Ding et al, 2010; Chua et al, 2011; Chiang et al, 2012; Pichler et al, 2013).

Leukocytes are mainly composed of neutrophils and lymphocytes. Lymphocytes are involved in cytotoxic cell death and cytokine production, which inhibits proliferation and metastatic capacity of tumour cells by immune response against the tumour (Ownby et al, 1983). In recent studies, normalisation of an initial lymphocytopenia in breast cancer patients treated with chemotherapy leads to an increased clinical outcome (Nieto et al, 2004), and an elevated lymphocyte count was significantly associated with prolonged OS in patients with multiple myeloma (Ege et al, 2008).

In colorectal cancer patients, tumour-infiltrating lymphocytes have been shown to be independent prognostic factors of survival in all clinical stages (Ropponen et al, 1997). Furthermore, lymphocytosis was found to be significantly associated with increased OS in metastatic colorectal cancer patients (Leitch et al, 2007). Elevated neutrophil counts, however, may reflect tumour progression by providing an adequate environment for its growth. The presence of intratumoural neutrophils was significantly associated with larger tumour size and decreased survival in a study including patients with renal cell carcinoma (Jensen et al, 2009). Elevated blood neutrophil counts lead to poor progression-free survival (PFS) and OS in a study cohort including 1410 patients with nasopharyngeal cancer (He et al, 2012).

A combined index using neutrophil and lymphocyte counts has already been shown to predict colorectal cancer survival. Chua et al (2011) found that a NLR >5 is associated with worse OS in patients with metastatic colorectal cancer, while normalisation of the NLR after one cycle of chemotherapy resulted in improvement of PFS. Walsh et al (2005) showed an association between NLR >5 and...
and decreased OS in colorectal cancer patients of all clinical stages, whereas Ding et al (2010) found an association between a preoperative NLR > 4 and decreased recurrence-free survival in colon cancer patients who underwent surgery alone.

The first study evaluating the dNLR included 12,118 patients with various cancer entities and found a similar prognostic effect for dNLR and NLR (Proctor et al, 2012). However, they found a small but persistent superiority of the prognostic value of the NLR over the dNLR. The authors hypothesised that the dNLR is broadly mixing two cell types, lymphocytes and monocytes, with possible opposing effects in terms of predictive value. In the normal range, the relative proportion of lymphocytes to monocytes is approximately 6:1. Even though there may be a fall in the absolute proportion of lymphocytes and an increase in the absolute proportion of monocytes in cancer patients, the white blood count minus monocytes is dominated by lymphocytes. Therefore, the dNLR is likely to be a reasonable approximation of the NLR, and the potential error introduced by the presence of monocytes in the fraction is therefore likely to be small (Proctor et al, 2012).

When we applied the dNLR cut-off level provided by Proctor et al for OS to our study cohort, we found a significant association with OS in univariate but not in multivariate analysis. In NLR analyses, we found for both the ROC-optimised and the predefined literature-based cut-off levels a significant association between NLR and TTR and OS. However, there was a small but persistent superiority in predicting TTR and OS of the ROC based over the literature-based cut-off levels. This difference is likely to be due to the optimised ROC-analysis approach matching our study cohort. When we compared the prognostic value of ROC-based dNLR and NLR, we found a similar prognostic effect. However, similar to the study by Proctor et al, we found a small but persistent superiority of the prognostic value of the NLR over the dNLR.

When we compared the effect of the dNLR in patients who underwent surgery alone with that in patients who underwent surgery and adjuvant chemotherapy, we found in both groups a significant association between high dNLR and decreased TTR. However, the effect was superior in the group of patients who underwent curative surgery alone compared with patients who underwent adjuvant chemotherapy (HR of 3.44 vs 1.91, respectively). This may support the conclusion that a high dNLR is a negative prognostic marker, and that such high-risk patients may benefit from adjuvant chemotherapy. The exact mechanism, however, how chemotherapy effects on dNLR and vice versa remains to be determined.

The strengths of our study are the well-defined study cohort and the narrow time frame for blood collection within 3 days before surgery, excluding possible clinical significant infections. However, because of the retrospective design of our study, a selection bias cannot be fully excluded. Furthermore, because of the exploratory nature of this study, we calculated optimised dNLR cut-off levels for TTR and OS using ROC analysis. If different cut-off levels for different endpoints are valuable or if one threshold level can reliably predict different endpoints needs to be determined in validation studies.

In summary, the results of the present study show that the dNLR may be an independent prognostic marker for TTR and OS in patients with stage II and III colon cancer. Independent validation of our findings is warranted.

**REFERENCES**

Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe, 2004. *Ann Oncol* 16: 481–488.

Chiang SF, Hung HY, Tang R, Changchien CR, Chen JS, You YT, Chiang JM, Lin JR (2012) Can neutrophil-to-lymphocyte ratio predict the survival of colorectal cancer patients who have received curative surgery electively? *Int J Colorectal Dis* 27: 1347–1357.

Chua W, Charles KA, Baracos VE, Clarke SJ (2011) Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. *Br J Cancer* 104: 1288–1295.

Ding PR, An X, Zhang RX, Fang YJ, Li LR, Chen G, Wu XJ, Lu ZH, Lin JZ, Kong LH, Wan DS, Pan ZZ (2010) Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIIA colon cancer. *Int J Colorectal Dis* 25: 1427–1433.

Ege H, Gertz MA, Markovic SN, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, Porvata LF (2008) Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study. *Br J Haematol* 141: 792–798.

Gill S, Loprinzi CL, Sargent DJ, Thone SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM (2004) Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? *J Clin Oncol* 22: 1797–1806.

Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ (2013) The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. *Crit Rev Oncol Hematol* e-pub ahead of print 16 April 2013; doi: 10.1016/j.critrevonc.2013.03.010.

Halazun KJ, Hardy MA, Rana AA, Woodland 4th DC, Luyten EJ, Mahadev S, Witkowski P, Siegel AB, Brown JR RS, Emond JC (2009) Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. *Ann Surg Oncol* 250: 141–151.

He JR, Shen GP, Ren ZF, Qin H, Cui C, Zhang Y, Zeng YX, Jia WH (2012) Pretreatment levels of peripheral neutrophils and lymphocytes as independent prognostic factors in patients with nasopharyngeal carcinoma. *Head Neck* 34: 1769–1776.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. *CA Cancer J Clin* 58: 7–96.

Jensen HK, Donskov F, Marcussen N, Nordmark M, Lundbeck F, van der Maase H (2009) Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. *J Clin Oncol* 27: 4709–4717.

Kishi Y, Koptez S, Chun YS, Palavecino M, Abdalla EK, Vauthy JN (2009) Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. *Ann Surg Oncol* 16: 614–622.

Le Voyer TE, Sigurdson ER, Hanlon AL, Mayer RJ, Macdonald JS, Catalano PJ, Haller DG (2003) Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. *J Clin Oncol* 21: 2912–2919.

Lee YY, Choi CH, Kim HJ, Kim TJ, Lee JW, Lee JH, Bae DS, Kim BG (2012) Pretreatment neutrophil/lymphocyte ratio as a prognostic factor in cervical carcinoma. *Anticancer Res* 32: 1555–1561.

Leitch EF, Chakrabarti M, Crozier JE, McKee JE, Anderson JH, Horgan PG, McMillan DC (2007) Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. *Br J Cancer* 97: 1266–1270.

Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. *Nature* 454: 436–444.

Morris M, Platell C, de Boer B, McCaul K, Iacopetta B (2006) Population-based study of prognostic factors in stage II colon cancer. *Br J Surg* 93: 866–871.

Nieto Y, Nawaz S, Shpall EJ, Bearman SI, Murphy J, Jones RB (2004) Long-term analysis and prospective validation of a prognostic model for patients with high-risk primary breast cancer receiving high-dose chemotherapy. *Clin Cancer Res* 10: 2609–2617.

O’Connell JB, Maggard MA, Ko CY (2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. *J Natl Cancer Inst* 96: 1420–1425.

www.bjcancer.com | DOI:10.1038/bjc.2013.346
Ownby HE, Roi LD, Isenberg RR, Brennan MJ (1983) Peripheral lymphocyte and eosinophil counts as indicators of prognosis in primary breast cancer. Cancer 52: 126–130.

Pichler M, Hutterer GC, Stoeckigt C, Chrozech TF, Stojakovic T, Golbeck S, Eberhard K, Gerger A, Mannweiler S, Pummer K, Zigeuner R (2013) Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. Br J Cancer 108: 901–907.

Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ (2012) A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer 107: 695–699.

Quah HM, Chou JF, Gonen M, Shia J, Schrag D, Landmann RG, Guillem JG, Paty PB, Temple LK, Wong WD, Weiser MR (2008) Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum 51: 503–507.

Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM (1997) Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 182: 318–324.

Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cesar L, Labianca R, Cunningham D, Van Cutsem E, Bosman F (2010) Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28: 466–474.

Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C, Lopez-Doriga A, Santos C, Marijnen C, Westerga J, Bruin S, Kerr D, Kuppen P, van de Velde C, Morreau H, Van Velthuyse M, Glas AM, Van’t Veer LJ, Tollsenaar R (2011) Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 29: 17–24.

Sarraf KM, Belcher E, Raesys E, Nicholson AG, Goldstraw P, Lim E (2009) Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg 137: 425–428.

Schmoll HJ, Van Cutsem E, Stein A, Valenti V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Kohne CH, Labianca R, Price T, Scheithauer W, Sobiero A, Taberner O, Aderka D, Barroso S, Bodoky G, Douillard JY, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Soulakos I, Turhal S, Cervantes A (2012) ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 23: 2479–2516.

Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ (2005) Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 91: 181–184.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.

Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)